Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes.

Lower numbers of severe hypoglycaemia were also observed in the dapagliflozin group (HR 0.45 [95% CI 0.05‐3.76]); however, because there were very few hypoglycaemic events it did not reach statistical significance (Table 3 ). 3.5 Sensitivity analysis When assessing new users of dapagliflozin, DPP‐4 inhibitors or insulin, whichever came first to define the novel and insulin group, the number of patients who were able to be matched decreased to 17 848 and the groups were similar at baseline (data not shown).

also in 111,027 other papers